Erliso 1MG /10ML

Price 2236 INR/ Thousand

Get a Price/Quote

MOQ : 5 Vials

Erliso 1MG /10ML Specification

Origin of Medicine
India

Salt Composition
Erlotinib (1mg/10ml)

Indication
Treatment of advanced or metastatic non-small cell lung cancer and locally advanced, unresectable or metastatic pancreatic cancer

Pacakaging (Quantity Per Box)
1 vial per box

Dosage Form
Injection

Drug Type
Allopathic

Ingredients
Erlotinib Hydrochloride

Physical Form
Liquid

Function
Anti-cancer agent, Tyrosine kinase inhibitor

Recommended For
Non-small Cell Lung Cancer (NSCLC), Pancreatic Cancer

Dosage
As prescribed by the physician

Dosage Guidelines
Take as directed by healthcare professional

Suitable For
Adults

Quantity
10 ml per vial

Storage Instructions
Store below 30C, protect from light

Usage
Hospital and clinical use under medical supervision

Regulatory Status
Approved for oncology use as per regulatory norms in India

Brand Name
Erliso

Prescription Required
Yes

Route of Administration
Intravenous

Warning and Precautions
To be administered by trained professionals only. Monitor patient for adverse reactions.

Marketed By
Celon Laboratories Ltd.

Shelf Life
Check vial for expiry, generally 24 months from manufacture

Container Type
Glass Vial

Side Effects
May include rash, diarrhea, fatigue, loss of appetite, and interstitial lung disease. Consult doctor for complete list.

Appearance
Clear, colourless to pale yellow solution

About Erliso 1MG /10ML

Erliso Injection is used in the treatment of bleeding esophageal varices (bleeding from dilated veins in the food pipe leading to your stomach). It narrows the walls of blood vessels and decreases the blood flow into the affected veins.Erliso Injection is given by a healthcare professional. You should not self-administer this medicine at home. Your doctor will decide the dose and how often you should take them. It is given only to patients with severe or life-threatening bleeding in the food pipe (esophagus).Using this medicine can cause some common side effects such as headaches, slow heart rate, high blood pressure, peripheral vasoconstriction, and Peripheral ischemia low blood pressure. Let your doctor know if any of these side effects do not go away or get worse.Before using this medicine, inform your doctor if you have any problems with your heart, liver, or kidneys. You should also tell your doctor all the other medicines you are taking. This medicine is not recommended for children and adolescen

Targeted Anti-Cancer Therapy

Erliso is a potent tyrosine kinase inhibitor aimed at blocking the growth signals in cancer cells, specifically for non-small cell lung cancer and certain types of pancreatic cancer. As an advanced therapy, it helps to target tumors with precision, potentially improving treatment outcomes for eligible patients under strict medical supervision.

Safe and Controlled Administration

This medicine is administered intravenously in hospitals and clinics by trained healthcare professionals only. This controlled process ensures accurate dosage and immediate medical attention in case of any adverse reactions. Prior to administration, each vials expiry and appearance are checked to maintain sterility and effectiveness.

Comprehensive Patient Monitoring

Erliso requires ongoing patient assessment to monitor for side effects, which may include rash, diarrhea, or fatigue. Dedicated oncology teams ensure any complications are managed rapidly, making it a safe option for those requiring complex cancer care. Patients must follow physician guidance closely throughout the treatment course.

FAQs of Erliso 1MG /10ML:

Q: How is Erliso 1MG/10ML administered?

A: Erliso is administered intravenously by a trained medical professional in a hospital or clinical setting. Dosage and frequency are determined by your physician based on your condition and response to treatment.

Q: What are the main uses of Erliso 1MG/10ML?

A: Erliso is used for the treatment of adults with advanced or metastatic non-small cell lung cancer (NSCLC) and locally advanced, unresectable, or metastatic pancreatic cancer. It targets cancer cells to help slow or stop tumor growth.

Q: When should Erliso 1MG/10ML treatment be considered?

A: This medication is prescribed by oncologists when patients are diagnosed with eligible forms of lung or pancreatic cancer and require targeted therapy. It is administered only after careful patient evaluation and under medical supervision.

Q: Where should Erliso 1MG/10ML be stored and handled?

A: Store Erliso below 30C and protect it from light. Handling and administration should occur in a hospital or clinic, ensuring a safe and controlled environment for patients.

Q: What is the process for receiving Erliso 1MG/10ML?

A: You will first need a prescription from your oncologist. Once prescribed, Erliso is administered through an intravenous infusion by qualified staff, with patient monitoring for any side effects before and after the procedure.

Q: What benefits does Erliso 1MG/10ML offer for patients?

A: Erliso provides targeted inhibition of cancer cell growth, offering potential improvement in disease control for those with certain lung and pancreatic cancers. Its precision approach means it acts specifically on cancerous tissues under professional supervision.

Q: What precautions should be taken during Erliso 1MG/10ML treatment?

A: Only healthcare professionals should handle and administer this injection. Patients are closely monitored for side effects such as rash or fatigue. If any abnormal reactions occur, inform your medical team immediately for appropriate management.

Tell us about your requirement